Tuesday's election eliminated some uncertainty around health-care reform, but the market is still undervaluing several firms in the sector, say Morningstar's Alex Morozov and Matt Coffina.
Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.
Associate director for health-care analysis Alex Morozov on the uncertainty-overhang relief, biggest winners, and best values in post-reform health care.
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Four offerings deemed to be right for right now.
Morningstar markets editor Jeremy Glaser sizes up the scenarios on the fiscal cliff, health-care reform, Fed policy, bank regulation, and more following this week's election.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.
Morningstar hosted its second ETF Invest Conference Sept. 22-23 in Chicago.
Morningstar's Damien Conover says that current reform proposals are more like a slingshot than a rifle aimed at pharmaceutical companies--which are currently priced for a worst-case scenario.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.